ResearchResearch summary
Probiotic Saccharomyces boulardii and fungal infections
A five-hospital Finnish review found an association with Saccharomyces cultures, but did not estimate risk among probiotic users or prove causation.
In this pathway
- Current topic
- Probiotic Saccharomyces boulardii and fungal infectionsCurrent

Bottom line
This Finnish hospital study found an association between documented use of the live yeast probiotic Saccharomyces boulardii and Saccharomyces-positive cultures. It does not show how often infection occurs among probiotic users or prove that the probiotic caused each case.
Why this source matters
Fungemia linked to S. boulardii had previously been reported mainly in individual cases and small series. This five-hospital review adds a larger, systematically assembled set of hospital culture findings and same-ward comparisons, including nonblood samples.
Study and population
Researchers reviewed records for Saccharomyces-positive cultures at five Finnish university hospitals from January 2009 through December 2018. Their combined catchments covered 3.29 million of Finland's 5.6 million residents. The study included 46 patients with Saccharomyces in blood cultures. It also identified 1,153 nonblood culture findings, excluding stool; records were reviewed for only the most recent 25 eligible cases per hospital district (125 total). Controls were other same-ward patients with positive blood or clinical cultures. This was not a population-risk study.
What was assessed
The team checked medical records for use of S. boulardii around the time of a positive culture. Records identified the same Precosa strain, and 16 of the 20 blood-case patients with confirmed recent use received it in hospital, 3 in another facility, and 1 at home. Routine clinical laboratories often report S. boulardii as Saccharomyces species or S. cerevisiae, so the investigators did not establish a molecular match between each probiotic and clinical isolate. Exposure windows also differed between methods and tables.
Results
At least 20/46 (43%) patients with fungemia had documented probiotic use on the culture date or in the prior 7 days. Ten records were unavailable and these patients were counted as nonusers. The table reports 4/76 (5%) use among blood-culture controls and an odds ratio of 14 (95% CI 4–44), although the methods describe a longer control exposure window than the table.
Among selected nonblood cases, use was confirmed in 24/125 (19%), compared with 3/123 (2%) controls (OR 10, 95% CI 3–32). The 125 reviewed cases were the most recent eligible cases per district, not a random sample of all 1,153 findings. Some samples may reflect colonization; Table 3 also used different exposure windows by district.
Antifungal treatment was started or changed for 23/46 fungemia cases. For 8/46, the culture result came after death. Case fatality was 10/46 by day 7 and 17/46 by day 28. Antifungal medication changed for 44/125 reviewed nonblood findings. These figures describe selected hospitalized patients, not deaths attributed to the probiotic.
Applicability
The findings concern one live yeast probiotic strain recorded in five Finnish hospitals and patients who already had positive cultures. They cannot estimate the risk for a person using S. boulardii, the risk for the general population, or the effect of bacterial probiotics. The study was about Saccharomyces cultures, not Candida treatment or probiotic efficacy for vaginal symptoms.
Limitations
This retrospective study had no denominator of probiotic users or population-at-risk person-time. Same-ward culture-positive controls and patient selection leave room for confounding by illness and healthcare exposure. Missing records were counted as no use, and routine laboratories could not confirm a probiotic-to-isolate strain match. Exposure windows were inconsistent. Some nonblood cultures may have represented colonization. The authors described one case as caused by accidental peritoneal administration after a feeding tube was displaced, but that specific event does not establish causation for the other cases.
Contribution to the evidence
Supporting safety context. The study quantifies an association in selected hospital patients and makes the size of the observed culture-positive groups visible. The authors concluded that S. boulardii probiotics are not recommended for people with indwelling catheters, immunocompromise, or critical illness, and should be considered carefully when gastrointestinal integrity might be compromised. This is the authors’ interpretation of an observational association, not an estimate of user risk or a new locale-independent action; existing locale-specific safety records and routes remain unchanged. The study does not establish general probiotic harm or a causal effect for each case.
Practical change
No change to Candida treatment claims or general probiotic advice. The findings support careful review of the exact live yeast product in high-risk situations already addressed by locale-specific authorities. They do not justify a universal prohibition or a new care route.
Funding and conflicts
The study was supported by a Finnish Medical Foundation scholarship (grant 2903 to J.R.) and Competitive State Research Financing of Tampere University Hospital (grant 92010 to R.H.). All authors except Ulla Hohenthal reported no relevant financial relationships. Hohenthal disclosed advisor or consultant service for GlaxoSmithKline and other relationships, including congress travel, with Grifols Nordic AB and Merck Sharp & Dohme GmbH.
Source
Read the original article, originally published online July 14, 2021, in the August 2021 issue of Emerging Infectious Diseases.
Study type, population, and sample scale
- Study type
- Retrospective registry and medical-record review with same-ward culture-positive controls
- Population
- Patients with Saccharomyces-positive blood or other clinical cultures at five Finnish university hospitals from 2009 through 2018; controls were selected from patients with other positive cultures on the same wards
- Sample scale
- 46 blood-culture cases; 1,153 nonblood culture findings, of which the most recent 25 eligible cases per hospital district were reviewed (125 records); 76 blood-culture and 123 nonblood-culture controls
Results
- At least 20/46 (43%) patients with Saccharomyces fungemia had documented S. boulardii use on the culture date or in the preceding 7 days; 10/46 records were unavailable and those patients were classified as nonusers. Table 2 also reports use within 3 months for 25/46 (54%).
- Table 2 reports use in 4/76 (5%) blood-culture controls and an odds ratio of 14 (95% CI 4–44). The methods describe case exposure within 7 days but control exposure within 3 months, while the table labels the control figure as preceding 7 days.
- Among 1,153 nonblood findings, the most recent 25 eligible cases per hospital district were reviewed, excluding fecal samples. Use was confirmed in 24/125 (19%); six records were unavailable. Controls reported use in 3/123 (2%) (OR 10, 95% CI 3–32). Table 3 reports 3-month exposure for Kuopio and 7-day exposure elsewhere; some nonblood findings may have represented colonization.
- Antifungal treatment was started or changed for 23/46 (50%) fungemia cases; 8/46 (17%) culture results arrived after death. Case fatality was 10/46 (22%) by day 7 and 17/46 (37%) by day 28. For nonblood findings, antifungal medication changed in 44/125 (35%). These outcomes describe selected hospitalized patients and are not estimates of deaths caused by probiotic use.
Limitations
- The registry covered hospital culture findings across catchments serving 3.29 million of Finland's 5.6 million residents.
- Catchment population is not a denominator of probiotic users or population-at-risk person-time; this study does not estimate incidence or user risk.
- Cases and controls were selected from patients with positive cultures in the same hospital wards.
- This hospital case-control comparison does not establish the association in community probiotic users and may reflect underlying illness, healthcare exposure, or other confounding.
- Records unavailable for 10/46 blood cases and 6/125 reviewed nonblood cases were classified as nonusers.
- Confirmed exposure proportions are minimum estimates and may be affected by missing documentation.
- Routine laboratory identification often cannot distinguish S. boulardii from S. cerevisiae.
- The investigators did not molecularly confirm that the clinical isolate matched the probiotic strain; most recorded products were the same Precosa strain.
- Exposure windows are inconsistent across methods and tables.
- Blood-case exposure is defined within 7 days, but the methods describe controls over 3 months while Table 2 labels 4/76 controls as preceding 7 days. For nonblood findings, methods describe up to 3 months while Table 3 uses 3 months for Kuopio and 7 days elsewhere.
- Some nonblood Saccharomyces-positive samples may represent colonization.
- A positive culture and subsequent medication change do not establish invasive infection or that probiotic use caused the finding.
- The authors describe one case as unequivocally caused by accidental peritoneal administration of the probiotic after feeding-tube displacement.
- This specific administration error does not make the broader observational association causal.
Applies to
- Documented S. boulardii use among selected patients with Saccharomyces-positive clinical cultures in five Finnish university hospitals during 2009–2018
- A hospital case-control association between probiotic use and Saccharomyces-positive cultures in the study's selected groups
Does not apply to
- The probability of infection or death among people who use S. boulardii, or incidence in the Finnish or general population
- Causation for every positive culture, a product-wide prohibition, or risk from bacterial probiotics generally
- Candida treatment efficacy, probiotic efficacy for vaginal symptoms, or the meaning of every nonblood Saccharomyces culture
Contribution to the current conclusion
Supporting
The study supports a safety signal for documented live S. boulardii use among selected hospital patients with Saccharomyces-positive cultures. It has no denominator of product users, cannot estimate user risk or population incidence, and does not establish that the probiotic caused each infection or that bacterial probiotics share the signal.
Related evidence mapPractical change or no change
No change to Candida efficacy claims, general probiotic guidance, or locale-specific care routes. The study adds a bounded safety signal for live S. boulardii in selected hospital patients but cannot estimate risk among users or establish a universal prohibition. Existing high-risk review remains governed by current locale-specific authority sources.
Funding and conflicts
- Funding
- Supported by a Finnish Medical Foundation scholarship (grant 2903 to J.R.) and Competitive State Research Financing of Tampere University Hospital (grant 92010 to R.H.).
- Conflicts
- All authors except Ulla Hohenthal reported no relevant financial relationships. Hohenthal disclosed advisor or consultant service for GlaxoSmithKline and other relationships, including congress travel, with Grifols Nordic AB and Merck Sharp & Dohme GmbH.
- Paper date
- 2021-07-14
Sources
View all 1 source
- Fungemia and Other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements
- Source type
- Observational study
- Published
- 2021-07-14